Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Using Integrative Medicine Approaches for Cancer-Related Fatigue

September 12, 2018
By Lori Smith, BSN, MSN, CRNP
Article

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches, explained researchers of a recent study. The researchers’ objective was to evaluate the effect of integrative medicine on those with both early and advanced breast and gynecologic malignancies receiving chemotherapy as treatment. What they found was that the use of integrative medicine may help alleviate some of the fatigue experienced by these patients.

“Fatigue is almost always multifactorial. Chemotherapy can increase fatigue by causing anemia, poor sleep, suppression of endogenous corticosteroids, release of pro-inflammatory cytokines, and poor nutrition from reduced appetite and increased nausea,” said Gary Deng, MD, PhD, medical director of the integrative medicine service at Memorial Sloan Kettering Cancer Center in New York, who was not involved in this research.

The study, published in Supportive Care in Cancer, which was conducted between June 2013 and May 2016, included 258 patients with early- to late-stage gynecologic or breast cancers undergoing treatment with adjuvant, neoadjuvant, or palliative chemotherapy. Study participants were evaluated at baseline and then at their 6- and 12-week follow-up appointments. Assessments included evaluation of quality of life, cancer-related fatigue, and routine hemoglobin levels. In addition, the relative dose intensity was assessed during the 6- and 12-week visits.

Researchers led by Eran Ben-Arye, MD, of the integrative oncology program at Lin and Carmel Medical Centers, Clalit Health Services in Haifa, Israel, found improvement in fatigue at both the 6- and 12-week follow-up evaluations in study participants treated with integrative medicine modalities, such as acupuncture, mind-body-spirit therapies, touch/movement therapies, and herbal/nutritional interventions. The researchers noted that acupuncture was used to treat the 120 study participants who were optimally assessed during the trial, adding that most of the participants underwent simultaneous treatment with at least two integrative medicine methods.

“It is imperative to take a holistic approach in treating [fatigue],” noted Deng. “The ‘one-symptom, one-drug’ approach would miss the mark. Therefore, we have to take a multidisciplinary approach to address all contributing factors.”

Although fatigue levels improved in the treatment arm of the study, hemoglobin levels were noted to decline in those treated with integrated medicine. “The relationship between improved fatigue levels despite reduced hemoglobin levels in complementary and alternative medicine–treated patients, which was reported in the present study, needs to be better understood,” noted the researchers.

“Because of the complexity in managing fatigue, research in this area is challenging. What would constitute the combination of “secret ingredients” that produces optimal clinical benefit is very difficult to tease out. On the other hand, fatigue is so prevalent among cancer patients, and we currently have no reliable treatment that gives us satisfactory results. Any research to explore new approaches would be very much needed,” stressed Deng.

Recent Videos
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Related Content
Advertisement

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC

Roman Fabbricatore
October 16th 2025
Article

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.


Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Russ Conroy
October 13th 2025
Article

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Related Content
Advertisement

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer

Kyle Doherty
October 17th 2025
Article

Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.

Pembrolizumab/Chemotherapy Improves Survival in Recurrent PROC

Roman Fabbricatore
October 16th 2025
Article

The safety profile of pembrolizumab plus chemotherapy with or without bevacizumab was consistent with that observed in previous studies.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with P53 abnormal endometrial cancer.

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Roman Fabbricatore
October 13th 2025
Article

The most pronounced overall and recurrence-free survival benefit with chemoradiotherapy was observed among patients with TP53-abnormal endometrial cancer.


Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Russ Conroy
October 13th 2025
Article

Trials slated for presentation at the 2025 ESMO Congress may reveal practice-changing data across different breast and lung cancer populations.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.